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Background: Copy number variations (CNVs) can play an important role in tumor genesis and growth 
through amplification of oncogenes and loss of tumor suppressor genes. Consequently, identification of 
cancer specific somatic CNVs can provide insight into cancer diagnosis, prognosis and treatment.  Recent 
advances in high throughput next generation sequencing (NGS) technologies have created an opportunity 
for  detecting  CNVs  with  higher  accuracy  and  resolution  than  previous  technologies  such  as  array-
comparative  genomic  hybridization.  As  a  result,  several  sequence-based  CNV  detection  methods  and 
software  applications  have  been  developed  to  take  advantage  of  these  technologies.  However,  no 
comprehensive comparison of the sensitivity and precision of the most recent sequence-based tools has 
been  performed.  The  results  of  this  work  indicate  the  performance  characteristics  of  the  recent 
sequence-based  CNV  detection  tools,  which  can  facilitate  selection  of  an  appropriate  tool  for  cancer 
studies and serve as a guide to develop new algorithms that address current limitations. 
Results: In this work, we analyze the performance of six new publically available sequence-based CNV 
detection  tools  (SegSeq,  CNVer,  CNVnator,  FREEC,  CNV-seq  and  ReadDepth),  using  six  synthesized 
datasets, characterized by different coverage values (0.5, 2, 5, 10, 20 and 50) and contained known CNVs, 
and eight low coverage breast cancer cell line (MCF7, T47D, BT474, ZR75-1, BT20, MDA-MB-231, MDA-
MB-468 and HCC1143) NGS datasets.  The synthesized NGS 
datasets are used to accurately compute sensitivity (Figure 
1a), precision and breakpoint accuracy of the tools while 
increasing sequence coverage. Breast cancer cell line NGS 
datasets are used to calculate sensitivity and precision of 
the tools (Figure 1b), analyze statistical characteristics of 
the  detected  CNVs  and  compare  the  computational 
requirements and costs of the tools employing default and 
a range of the key parameters’ values.  
Conclusion:  The  sensitivity  and  breakpoint  accuracy  of 
CNV detection tools, using synthesized and breast cancer 
cell  lines  NGS  datasets,  indicate  tools  that  employ  more 
computationally  complex  and  elaborate  detection 
algorithms;  and  tools  that  incorporate  information 
embedded  in  paired-end  data  and  depth  of  coverage, 
perform better than other tools (in average 30% increase 
in  sensitivity  and  6%  increase  in  break  point  accuracy. 
However, the computational cost of the better performing 
tools is higher than the other methods (about one order of 
magnitude).  Also, this study shows that the precision of 
current CNV detection tools is still low (43% in average) 
and  indicates  the  likelihood  of  high  false  positive  rate. 
There is also a disturbing lack of CNV prediction consensus 
across  tools  –  even  those  high  performing  methods. 
Current  methods  for  detecting  CNV  by  analysis  of  NGS 
sequence of cancer genomes do not yet provide the level of 
accuracy  and  robustness  required  to  predict  CNVs  with 
high  confidence.    This  study  demonstrates  the  need  for 
further work on both the quality of NGS data and on the 
development  and  refinement  of  sequence-based  CNV 
detection algorithms.  
Figure  1.  (a)  Sensitivity  of  the  tools  vs.  coverage 
using synthesized NGS datasets. (b) Sensitivity and 
precision of the tools against MCF7 cell line 
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